Sixth Annual RNAi Roundtable Series - TTRsc02 on Monday next week | ALNY Message Board Posts

Alnylam Pharmaceuticals

  ALNY website

ALNY   /  Message Board  /  Read Message

 

 






Keyword
Subject
Between
and
Rec'd By
Authored By
Minimum Recs
  
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board
Msg  34690 of 34858  at  9/12/2019 3:56:34 PM  by

evernewbliss


 In response to msg 34689 by  Steve_382
view thread

Re: Sixth Annual RNAi Roundtable Series - TTRsc02 on Monday next week

I think IONS/AKCA will be presenting P1 data on TTR-Lrx tomorrow. That is their next generation TTR drug that will compete with TTRsc02. It will be interesting to see what they report. I expect it to be safe and more potent than Tegsedi. Tegsedi and Onpattro will be obsolete in a few years.

I donít see any rational of moving Patisiran in P3 for cardiomyopathy when other Subq options - TTRsc02/TTR-Lrx - are right behind Patisiran. They should have moved Patisiran instead of Revusiran in P3 for cardiomyopathy several years ago. They are just trying to correct their old mistake after delay of several years and trying to position Patisiran as competition for Tafamidis. It will be tough for IV to compete with oral drug.


     e-mail to a friend      printer-friendly     add to library      
| More
Recs: 1     Views: 153
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board






Financial Market Data provided by
.


Loading...